RAS Dialogue
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
Tissue Health Prevails: KRAS Mutant Cells are Outcompeted from Adult Pancreas TissuesNot all RAS mutations in pancreatic tissue lead to cancer. Cells that acquire RAS mutations can be outcompeted by healthy, neighbouring cells, with the EphA2 receptor playing an important role in this process
-
A Spirit of Scientific Creativity and Excitement: Celebrating the Career of Dr. Jim HartleyJim Hartley, recently retired, was a creative force in the molecular biology field for over four decades. Throughout his career, he patented many of his ideas, including the Gateway cloning system which revolutionized protein expression
-
SHP2 Inhibitors for Treating CancerMany cancers have adaptations that allow them to resist cancer treatments. Inhibitors of SHP2, an important regulator of RAS-MAPK signaling, are being tested in human trials to make other cancer drugs more effective.
-
RAS-binding compounds: approaching the undruggable from a different perspectiveSmall antibody derivatives called nanobodies have been discovered that inhibit RAS functions in living cells. Drug candidates can be developed with assays in which they compete with nanobodies for RAS binding in vitro
-
Update: Mutations in Human Cancers Through the Lens of KRASKRAS is the most commonly mutated oncogene in human cancers. Analysis of the mutations in other genes in thousands of human tumors in which KRAS is highly mutated reveals patterns that may guide research into the biology of human cancers.